{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"8.2","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Everolimus 10 mg PO daily + Letrozole 2.5 mg PO daily + Metformin 500 mg PO twice daily on a 4 week schedule","id":"OG000","title":"Rad-Let-Met"}],"paramType":"MEDIAN","populationDescription":"54 participants were evaluable","reportingStatus":"POSTED","timeFrame":"93 months","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}